Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 45,20 € (+21,77%). La mediana è 46,19 € (+24,43%).
| Acquista |
3 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
LB Pharmaceuticals appoints Dr. Susan G. Kozauer as chief medical officer
LB Pharmaceuticals has appointed Dr. Susan G. Kozauer as chief medical officer. Kozauer brings more than 20 years of experience in developing neuropsychiatric drugs, most recently serving as senior vice president and head of clinical development at Centessa Pharmaceuticals. The appointment comes ahead of the expected topline results from the Phase 3 NOVA‑2 trial of LB‑102 for schizophrenia, anticipated in the first half of 2027. Kozauer holds a degree from Cornell, an MD from George Washington University, and completed a psychiatry residency at Georgetown University Hospital. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | -84,99K | - |
| Utile netto | -45,22 Mln | 947,33% |
| EBITDA | -47,16 Mln | 965,48% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,06 Mld € |
Numero di azioni | 28,68 Mln |
Massimo/minimo a 52 settimane | 43,71 € - 11,64 € |
| Dividendi | No |
Beta | 0,42 |
Rapporto P/E | -14,33 |
Rapporto PEG | -0,08 |
Rapporto P/B | 3,86 |
Rapporto P/S | 0,00 |
Profilo aziendale
Biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien für neuropsychiatrische Erkrankungen (z. B. Schizophrenie, bipolare Depression) entwickelt. Hauptkandidat ist LB-102, ein methyliertes Derivat von Amisulprid.
| Nome | LB Pharmaceuticals |
| CEO | Heather D. Turner |
| Sito web | |
| Quotazione in borsa | 11/09/2025 |
| Dipendenti | 49 |
